Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Shares of pharmaceutical companies declined after U.S. President Donald Trump announced plans to lower U.S. prescription drug ...

The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan ...

Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug ...

Shares of global pharma stocks slumped on Monday after President Trump vowed to cut drug prices for Americans by as much as 80%.

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...